<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00024232</url>
  </required_header>
  <id_info>
    <org_study_id>MSKCC-01030</org_study_id>
    <secondary_id>CDR0000068903</secondary_id>
    <secondary_id>NCI-G01-2013</secondary_id>
    <nct_id>NCT00024232</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>Pilot Trial of Humanized Monoclonal Antibody J591 in Patients With Progressive Androgen-Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy in treating&#xD;
      patients who have prostate cancer that has not responded to hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor effects of monoclonal antibody huJ591 in patients with&#xD;
           progressive androgen-independent prostate cancer.&#xD;
&#xD;
        -  Determine the biodistribution and dosimetry of this antibody in these patients.&#xD;
&#xD;
        -  Determine the effect on biodistribution of the delivery sequence of unlabeled vs indium&#xD;
           In 111-labeled antibody in these patients.&#xD;
&#xD;
        -  Determine the HAHA response in patients treated with this regimen.&#xD;
&#xD;
        -  Correlate the dose of monoclonal antibody huJ591 with antibody-dependent cellular&#xD;
           cytotoxicity in these patients.&#xD;
&#xD;
      OUTLINE: Patients are assigned to one of two treatment groups.&#xD;
&#xD;
        -  Group I: Patients receive monoclonal antibody huJ591 IV followed by indium In 111&#xD;
           monoclonal antibody huJ591 on day 1.&#xD;
&#xD;
        -  Group II: Patients receive monoclonal antibody huJ591 concurrently with indium In 111&#xD;
           monoclonal antibody huJ591 as in group I.&#xD;
&#xD;
      Treatment in both groups repeats every 3 weeks for 4 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for 4 weeks and then monthly for 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14 patients (7 per treatment group) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody huJ591</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer&#xD;
&#xD;
          -  Disease progression after prior castration&#xD;
&#xD;
               -  At least 3 rising PSA levels at least 1 week apart OR 2 rising levels at least 4&#xD;
                  weeks apart&#xD;
&#xD;
          -  New osseous lesions on bone scan and/or more than 25% increase in bidimensionally&#xD;
             measurable soft tissue disease or appearance of new sites of disease by CT scan or MRI&#xD;
&#xD;
          -  Testosterone no greater than 50 ng/mL&#xD;
&#xD;
               -  Medical therapy (e.g., gonadotropin-releasing hormone analogues) to maintain&#xD;
                  castrate level of testosterone should continue in the absence of surgical&#xD;
                  orchiectomy&#xD;
&#xD;
          -  Progression of disease after discontinuation of prior anti-androgen therapy&#xD;
&#xD;
          -  No requirement for palliative therapy within the past 12 weeks&#xD;
&#xD;
          -  No active CNS or epidural primary tumor OR active CNS or epidural metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,500/mm3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  Gamma-glutamyl-transferase less than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST less than ULN&#xD;
&#xD;
          -  PT less than 14 seconds&#xD;
&#xD;
          -  No prior autoimmune hepatitis&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinically significant cardiac disease (New York Heart Association class III or IV)&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe debilitating pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active uncontrolled infection or infection requiring IV antibiotics&#xD;
&#xD;
          -  No prior autoimmune disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior murine protein for diagnostic or therapeutic purposes&#xD;
&#xD;
          -  No other concurrent anticancer immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent anticancer hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Concurrent radiotherapy to localized sites of disease (e.g., bone) allowed if the site&#xD;
             does not contain sole measurable lesion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 4 weeks since prior therapeutic investigational anticancer drugs&#xD;
&#xD;
          -  At least 4 weeks since prior participation in therapeutic clinical trial with an&#xD;
             experimental drug&#xD;
&#xD;
          -  No prior diagnostic ProstaScint, Myoscint, or Oncoscint scans&#xD;
&#xD;
          -  No other concurrent therapeutic investigational anticancer agents&#xD;
&#xD;
          -  No concurrent participation in other therapeutic clinical trial with an experimental&#xD;
             drug&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Morris, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

